656 related articles for article (PubMed ID: 23480100)
21. A novel molecular marker of breast cancer stem cells identified by cell-SELEX method.
Lu M; Zhou L; Zheng X; Quan Y; Wang X; Zhou X; Ren J
Cancer Biomark; 2015; 15(2):163-70. PubMed ID: 25519016
[TBL] [Abstract][Full Text] [Related]
22. EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex.
Subramanian N; Kanwar JR; Athalya PK; Janakiraman N; Khetan V; Kanwar RK; Eluchuri S; Krishnakumar S
J Biomed Sci; 2015 Jan; 22():4. PubMed ID: 25576037
[TBL] [Abstract][Full Text] [Related]
23. A Flow Cytometry-based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer.
Nakhjavani M; Giles B; Strom M; Vi C; Attenborough S; Shigdar S
J Vis Exp; 2022 Sep; (187):. PubMed ID: 36190297
[TBL] [Abstract][Full Text] [Related]
24. A Fluorescent Imaging Probe Based on a Macrocyclic Scaffold That Binds to Cellular EpCAM.
Iwasaki K; Goto Y; Katoh T; Yamashita T; Kaneko S; Suga H
J Mol Evol; 2015 Dec; 81(5-6):210-7. PubMed ID: 26553371
[TBL] [Abstract][Full Text] [Related]
25. DNA aptamers from whole-cell SELEX as new diagnostic agents against glioblastoma multiforme cells.
Wu Q; Wang Y; Wang H; Wu L; Zhang H; Song Y; Zhu Z; Kang D; Yang C
Analyst; 2018 May; 143(10):2267-2275. PubMed ID: 29708252
[TBL] [Abstract][Full Text] [Related]
26. An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer.
Liu M; Wang Z; Tan T; Chen Z; Mou X; Yu X; Deng Y; Lu G; He N
Theranostics; 2018; 8(20):5772-5783. PubMed ID: 30555580
[TBL] [Abstract][Full Text] [Related]
27. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low.
Ring A; Mineyev N; Zhu W; Park E; Lomas C; Punj V; Yu M; Barrak D; Forte V; Porras T; Tripathy D; Lang JE
Oncotarget; 2015 Dec; 6(42):44623-34. PubMed ID: 26556851
[TBL] [Abstract][Full Text] [Related]
28. Pivotal role of CD38 biomarker in combination with CD24, EpCAM, and ALDH for identification of H460 derived lung cancer stem cells.
Karimi-Busheri F; Zadorozhny V; Li T; Lin H; Shawler DL; Fakhrai H
J Stem Cells; 2011; 6(1):9-20. PubMed ID: 22997842
[TBL] [Abstract][Full Text] [Related]
29. Probing the biophysical interaction between Neocarzinostatin toxin and EpCAM RNA aptamer.
Athyala PK; Kanwar JR; Alameen M; Kanwar RK; Krishnakumar S; Watson J; Vetrivel U; Narayanan J
Biochem Biophys Res Commun; 2016 Jan; 469(2):257-62. PubMed ID: 26642954
[TBL] [Abstract][Full Text] [Related]
30. A platform for primary tumor origin identification of circulating tumor cells via antibody cocktail-based in vivo capture and specific aptamer-based multicolor fluorescence imaging strategy.
Jia M; Mao Y; Wu C; Wang S; Zhang H
Anal Chim Acta; 2019 Nov; 1082():136-145. PubMed ID: 31472702
[TBL] [Abstract][Full Text] [Related]
31. An aptamer targeting shared tumor-specific peptide antigen of MAGE-A3 in multiple cancers.
Wang CY; Lin BL; Chen CH
Int J Cancer; 2016 Feb; 138(4):918-26. PubMed ID: 26314689
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo evaluation of therapy targeting epithelial-cell adhesion-molecule aptamers for non-small cell lung cancer.
Alibolandi M; Ramezani M; Abnous K; Sadeghi F; Atyabi F; Asouri M; Ahmadi AA; Hadizadeh F
J Control Release; 2015 Jul; 209():88-100. PubMed ID: 25912964
[TBL] [Abstract][Full Text] [Related]
33. Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors.
Xiang D; Zheng C; Zhou SF; Qiao S; Tran PH; Pu C; Li Y; Kong L; Kouzani AZ; Lin J; Liu K; Li L; Shigdar S; Duan W
Theranostics; 2015; 5(10):1083-97. PubMed ID: 26199647
[TBL] [Abstract][Full Text] [Related]
34. In vitro selection of aptamer S1 against MCF-7 human breast cancer cells.
Zhang WY; Chen HL; Chen QC
Bioorg Med Chem Lett; 2019 Aug; 29(16):2393-2397. PubMed ID: 31196711
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma.
Jiang S; Pei L; Yang ZL; Liu G
Hepatogastroenterology; 2014 May; 61(131):574-9. PubMed ID: 26176038
[TBL] [Abstract][Full Text] [Related]
36. Selection of aptamers for molecular recognition and characterization of cancer cells.
Tang Z; Shangguan D; Wang K; Shi H; Sefah K; Mallikratchy P; Chen HW; Li Y; Tan W
Anal Chem; 2007 Jul; 79(13):4900-7. PubMed ID: 17530817
[TBL] [Abstract][Full Text] [Related]
37. [Enhancement of thermal damage to EpCAM-positive tumor cells by novel aptamer-guided magnetic nanoparticles].
Zhang LY; Wang M; Wu HB; Yang Y; Li Q; Sun HL
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):726-731. PubMed ID: 29061014
[No Abstract] [Full Text] [Related]
38. The DNA aptamer binds stemness-enriched cancer cells in pancreatic cancer.
Kim YJ; Lee HS; Jung DE; Kim JM; Song SY
J Mol Recognit; 2017 Apr; 30(4):. PubMed ID: 27891685
[TBL] [Abstract][Full Text] [Related]
39. The use of sensitive chemical antibodies for diagnosis: detection of low levels of EpCAM in breast cancer.
Shigdar S; Qian C; Lv L; Pu C; Li Y; Li L; Marappan M; Lin J; Wang L; Duan W
PLoS One; 2013; 8(2):e57613. PubMed ID: 23460885
[TBL] [Abstract][Full Text] [Related]
40. Aptamer-based cell imaging reagents capable of fluorescence switching.
Jung YK; Woo MA; Soh HT; Park HG
Chem Commun (Camb); 2014 Oct; 50(82):12329-32. PubMed ID: 25182171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
